Lynx1 Capital Management LP Passage Bio, Inc. Transaction History
Lynx1 Capital Management LP
- $257 Million
- Q4 2024
A detailed history of Lynx1 Capital Management LP transactions in Passage Bio, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 9,256,953 shares of PASG stock, worth $4.81 Million. This represents 2.05% of its overall portfolio holdings.
Number of Shares
9,256,953
Previous 8,426,955
9.85%
Holding current value
$4.81 Million
Previous $5.9 Million
10.55%
% of portfolio
2.05%
Previous 2.11%
Shares
12 transactions
Others Institutions Holding PASG
# of Institutions
47Shares Held
37.7MCall Options Held
10.5KPut Options Held
0-
Orbimed Advisors LLC San Diego, CA7.4MShares$3.85 Million0.11% of portfolio
-
Vestal Point Capital, LP New York, NY6.1MShares$3.17 Million0.21% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$1.3 Million1.92% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.46MShares$1.28 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.07MShares$1.08 Million0.0% of portfolio
About Passage BIO, Inc.
- Ticker PASG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,463,200
- Market Cap $28.3M
- Description
- Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...